Control treatments in biologics trials of rheumatoid arthritis were often not deemed acceptable in the context of care

Journal of Clinical Epidemiology
Candice EstellatPhilippe Ravaud

Abstract

Control treatments in randomized controlled trials (RCTs) should not deliberately disadvantage patients. The objectives of the study were to compare (1) willingness to include vs. (2) willingness to prescribe control treatment among physicians randomized to assess, respectively, either (1) enrollment in a trial or (2) appropriateness of control treatment in a care context for the same fictional patient. Physicians were authors of articles about rheumatoid arthritis (RA), involved in RA patient care, and used to enrolling patients in trials. The outcomes were willingness to give control treatment: trial enrollment or control-treatment appropriateness in care context. We derived three case vignettes of fictional standard eligible patients for each of 30 RCTs assessing biologics in RA. Physicians were randomly allocated to the "trial" or "care" arm. For each of the 90 fictional patients, physicians assigned to the trial arm were asked if they would enroll the patient in the RCT the patient was derived from. For the same 90 fictional patients, physicians assigned to the care arm were asked if the control treatment of the RCT was appropriate in a context of usual care. Of the 1,779 physicians invited to participate, 151 were randomi...Continue Reading

References

Jul 16, 1987·The New England Journal of Medicine·B Freedman
Jan 1, 1997·Clinical Oncology : a Journal of the Royal College of Radiologists·D MachinJ B Whaley
Oct 31, 1998·BMJ : British Medical Journal·R Peto, C Baigent
Feb 13, 2002·Arthritis and Rheumatism·UNKNOWN American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines
Nov 13, 2002·Journal of the American Academy of Nurse Practitioners·Grace Newsome, UNKNOWN American College of Rheumatology
May 31, 2003·BMJ : British Medical Journal·Joel LexchinOtavio Clark
Apr 20, 1963·British Medical Journal·A B HILL
May 28, 2004·BMJ : British Medical Journal·Steven JoffeJane C Weeks
Sep 2, 2006·Arthritis and Rheumatism·Daniel AletahaMichael M Ward
Jun 16, 2007·Lancet·Josef S SmolenPaul Emery
May 7, 2008·Annals of Internal Medicine·Saul Malozowski
Jul 7, 2009·Implementation Science : IS·Susan HrisosMarie Johnston
Sep 3, 2009·JAMA : the Journal of the American Medical Association·Bridget M Kuehn
Jan 7, 2010·European Journal of Clinical Investigation·D N LathyrisJ P A Ioannidis
Feb 19, 2010·The New England Journal of Medicine·Jordan M VanLareHarold C Sox
May 4, 2010·Journal of Clinical Epidemiology·Harold C SoxPeter Tugwell
May 4, 2010·PLoS Medicine·Harold C SoxPeter Tugwell
Mar 18, 2011·Journal of Clinical Epidemiology·Evangelos C RizosJohn P A Ioannidis
Sep 21, 2011·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Jean-Christophe LucetPhilippe Ravaud
Sep 4, 2013·Nature Reviews. Rheumatology·John P A IoannidisEdward J Mills

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.